Al-Janabi A, Yiu ZZN. Psoriasis (Auckl). 2022;12:1–14.
The authors have advised that there is an error in Table 1 on page 2. The text “IL-7A” in the Target column for the Ixekizumab row should read “IL-17A”.
The authors apologize for this error.
. 2022 Jul 1;12:187–188. doi: 10.2147/PTT.S380486
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Received 2022 Jun 29; Accepted 2022 Jun 29; Collection date 2022.
© 2022 Al-Janabi et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
PMCID: PMC9255281 PMID: 35801229
This corrects the article "Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management" on page 1.